… where r A , r B , and r O are the effective ionic radii of A, B, and O ions, respectively. Usually,
this factor is evaluated from Shannon's ionic radii [49] for respective coordination numbers. …

The central involvement of estrogen in the development of the mammary gland and in the
genesis of breast cancer has lent impetus to studies of the links between estrogen action and …

… Rutai Hui contributed equally to the writing of this article. … 2009DFB30050 to Hui Rutai). …
Licht CM, de Geus EJ, van Dyck R, Penninx BW. Longitudinal evidence for unfavorable effects of …

Background Pembrolizumab is a humanized monoclonal antibody against programmed
death 1 (PD-1) that has antitumor activity in advanced non–small-cell lung cancer (NSCLC), …

Background We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition
with pembrolizumab in patients with advanced non–small-cell lung cancer enrolled in a …

Background First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …

Background The addition of pembrolizumab to neoadjuvant chemotherapy led to a
significantly higher percentage of patients with early triple-negative breast cancer having a …

Background An earlier analysis in this phase 3 trial showed that durvalumab significantly
prolonged progression-free survival, as compared with placebo, among patients with stage III, …

PURPOSE The phase III PACIFIC trial compared durvalumab with placebo in patients with
unresectable, stage III non–small-cell lung cancer and no disease progression after …

Background Most patients with locally advanced, unresectable, non–small-cell lung cancer (NSCLC)
have disease progression despite definitive chemoradiotherapy (chemotherapy …